Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass EstimatesZacks Investment Research • 08/06/26
Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/06/26
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 08/05/26
Earnings Preview: Sarepta Therapeutics (SRPT) Q2 Earnings Expected to DeclineZacks Investment Research • 07/29/26
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive OfficerBusiness Wire • 07/27/26
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT)GlobeNewsWire • 07/13/26
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout24/7 Wall Street • 07/10/26
Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26
All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to BuyZacks Investment Research • 06/08/26
Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?Zacks Investment Research • 06/05/26
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceBusiness Wire • 05/13/26
Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook MaintainedZacks Investment Research • 05/07/26
Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?Investors Business Daily • 05/07/26